Archives

SUNNYVALE, California -- BARRX Medical, Inc., a global technology leader in treating Barrett's esophagus, today announced the publication of two related European trials which report a 100% eradication rate for early esophageal cancer and pre-cancerous dysplasia using endoscopic resection followed by ablation therapy with the HALO ablation system. Barrett's esophagus is a complication of gastroesophageal reflux disease (GERD) and is a known risk factor for esophageal cancer, the fastest growing cancer in the Western world.

LONDON -- Researchers have unraveled a key mechanism by which smoking triggers genetic changes that cause lung cancer. Exposure to cigarette smoke slows production of a protein called FANCD2 in lung cells and this protein plays a key role in repairing damage to DNA, and causing faulty cells to commit suicide before they go on to become cancerous, BBC reported Wednesday, quoting a study by American researchers which appears in the British Journal of Cancer.

SANTA BARBARA, Calif. -- Six years ago, Senator Patty Murray (D-WA) first introduced her proposed legislation to ban asbestos and invest federal funding in the research critically needed to develop effective treatments for the vicious cancer, mesothelioma, and other asbestos related diseases. Since 2002, the Mesothelioma Applied Research Foundation (Meso Foundation) has worked closely with Senator Murray to stop the death and suffering and to get this life-saving legislation passed.

Hayden Bates didn't wait long - just a few weeks - to seek medical attention for headaches that wouldn't go away. When doctors discovered he had cancer at the base of his tongue, he was surprised, even though he knew, as a pack-a-day smoker since age 15, that tobacco use made him more susceptible to cancer in the mouth and throat. "You know how some of us be about the cigarettes," said Bates, 61, a Mississippi native and Springfield resident. "You can't get off of it overnight.

INDIANAPOLIS -- Lung cancer patients whose histology is factored into treatment decisions may fare better as a result, according to data from a pivotal non-small cell lung cancer (NSCLC) clinical trial. Data from the trial, which involved Eli Lilly and Company's ALIMTA(R) (pemetrexed for injection), will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., May 30 -- June 3, 2008.

INDIANAPOLIS -- Lung cancer patients whose histology is factored into treatment decisions may fare better as a result, according to data from a pivotal non-small cell lung cancer (NSCLC) clinical trial. Data from the trial, which involved Eli Lilly and Company's ALIMTA(R) (pemetrexed for injection), will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., May 30 -- June 3, 2008.

NEW YORK -- Pfizer announced today that study results across several difficult-to-treat cancers will be presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3, 2008. Pfizer will hold two briefings for journalists on June 1 and investors on June 2. Researchers will present the latest data from the breadth of Pfizer's oncology portfolio, focused in four areas of discovery: anti-angiogenesis, signal transduction, immuno-oncology and cytotoxics/potentiators.

WASHINGTON -- While lung cancer causes one in three cancer deaths, the National Cancer Institute (NCI) invested less than 5% of its $4.8 billion budget in lung cancer research in 2007, according to updated statistics issued by Lung Cancer Alliance (LCA) today. The two other federal agencies with significant cancer research programs -- Centers for Disease Control and Prevention (CDC) and the Department of Defense (DOD) -- have no money earmarked for lung cancer in 2007.

LONDON -- Researchers have unraveled a key mechanism by which smoking triggers genetic changes that cause lung cancer. Exposure to cigarette smoke slows production of a protein called FANCD2 in lung cells and this protein plays a key role in repairing damage to DNA, and causing faulty cells to commit suicide before they go on to become cancerous, BBC reported Wednesday, quoting a study by American researchers which appears in the British Journal of Cancer.

WINNIPEG, MANITOBA -- Miraculins Inc., a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, announces today that it will be conducting a 2nd pivotal pre-biopsy screen study for its urine based P2V(TM) prostate cancer diagnostic test. The study will focus on men who have been referred to a urologist and subsequently have been selected for a prostate biopsy, but will be restricted to men who have a PSA score of between 2.5ng/ml and 10 ng/ml with a normal DRE (digital rectal exam) result.